BioNexus Gene Lab (BGLC) Shares Outstanding (Diluted Average) (2023 - 2026)

BioNexus Gene Lab's Shares Outstanding (Diluted Average) history runs 4 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 34.54% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 34.54% YoY), while the FY2024 annual figure was $17.8 million, up 12.24% from the prior year.
• Shares Outstanding (Diluted Average) came in at $2.4 million for Q1 2026 at BioNexus Gene Lab, up from $1.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $17.8 million in Q4 2024 to a low of $1.8 million in Q2 2024.
• A 4-year average of $7.0 million and a median of $1.8 million in 2025 frame the typical range for Shares Outstanding (Diluted Average).
• Across the five-year window, Shares Outstanding (Diluted Average) sank 89.83% in 2025 and surged 34.54% in 2026, its largest moves.
• BioNexus Gene Lab's Shares Outstanding (Diluted Average) stood at $15.9 million in 2023, then increased by 12.24% to $17.8 million in 2024, then slumped by 89.92% to $1.8 million in 2025, then jumped by 34.55% to $2.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $2.4 million, $1.8 million, and $1.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison